广州达安基因股份有限公司 独立董事制度 第一章 总则 第一条 为进一步完善广州达安基因股份有限公司（以下简称"公司"）治 理结构，充分发挥独立董事在公司治理中的作用，促进公司独立董事尽责履职， 根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上市公司独立 董事管理办法》、《深圳证券交易所股票上市规则》、《深圳证券交易所上市公 司自律监管指引第1号——主板上市公司规范运作》等法律、法规、规章及《公 司章程》的规定，制定本制度。 第二条 独立董事是指不在公司担任除董事外的其他职务，并与公司及其主 要股东、实际控制人不存在直接或者间接利害关系，或者其他可能影响其进行独 立客观判断关系的董事。 独立董事应当独立履行职责，不受公司及其主要股东、实际控制人等单位或 者个人的影响。 第三条 独立董事对公司及全体股东负有忠实与勤勉义务，应当按照法律、 行政法规、中国证券监督管理委员会（以下简称"证监会"）的规定、深圳证券 交易所（以下简称"深交所"）业务规则和公司章程的规定，认真履行职责，在 董事会中发挥参与决策、监督制衡、专业咨询作用，维护上市公司整体利益，保 护中小股东合法权益。 第四条 公司独立董事占董事会成 ...

广州达安基因股份有限公司 独立董事专门会议审查意见 独立董事专门会议关于修改 2023 年度日常关联交易预计事项的 审查意见 根据中国证监会《上市公司独立董事管理办法》、《深圳证券交易所股票上 市规则》、《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司 规范运作》和《公司章程》等有关规定，我们作为公司的独立董事，于 2023 年 10 月 23 日召开了第八届董事会独立董事 2023 年第三次专门会议，本着实事求 是、认真负责的态度，公平、公正、诚实信用的原则，基于独立判断的立场，就 公司拟在第八届董事会 2023 年第二次临时会议审议的《关于修改 2023 年度日常 关联交易预计的议案》进行了审议，认真审阅了该关联交易事项相关资料，并且 与公司相关人员进行了有效沟通，现发表如下审查意见： 1、公司与关联方拟发生的关联交易是按照"公平自愿，互惠互利"的原则 进行的；交易价格按市场价格确定，定价公允，没有违反公开、公平、公正的原 则；公司应当按照相关规定履行董事会审批程序和相关信息披露义务。 2、公司修改的 2023 年度日常关联交易预计事项不存在损害公司和中小股东 的利益的行为，也不存在董事利用 ...

广州达安基因股份有限公司 网下新股申购管理办法 第一章 总则 第一条 为规范广州达安基因股份有限公司（下称"公司"）网下新股申购 业务，防范操作风险，确保网上和网下新股申购投资资金使用效益和安全，根据 《中华人民共和国证券法》、《证券发行与承销管理办法》、《首次公开发行证 券网下投资者管理规则》、《首次公开发行股票承销业务规范》、《首次公开发 行股票配售细则》、《上海市场首次公开发行股票网下发行实施细则》、《深圳 市场首次公开发行股票网下发行实施细则》等和国家有关法律、法规，结合公司 自身的实际情况，制定本办法。 第二章 基本定义 第二条 本办法所指的网下申购业务，是指公司以自有资金在指定时间内通 过上海证券交易所（以下简称"上交所"）或深圳证券交易所（以下简称"深交 所"）网下申购电子化平台（以下简称"申购平台"）及中国证券登记结算责任 有限公司登记结算平台（以下简称"结算平台"），参与拟上市公司首次公开发 行股票询价、申购，并在公司股票上市交易后出售获配股票的业务。 第三条 公司参与新股申购业务应遵守下列原则： 第三章 机构和职责 第四条 公司网下新股申购业务所涉及到的主要机构或部门有：首发证券定 价小组 ...

证券代码：002030 证券简称：达安基因 广州达安基因股份有限公司投资者关系活动记录表 编号：2023007 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动 | □媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | 类别 | □现场参观 | | | √其他（2023 广东辖区上市公司投资者关系管理月活 | | | 动投资者集体接待日） | | | 通过"全景•路演天下"（http://rs.p5w.net）参与 2023 广 | | 参与单位名称及 | 东辖区上市公司投资者关系管理月活动投资者集体接待日的 | | 人员姓名 | 广大投资者 | | 时间 | 2023-09-19（下午 15:45-17:00） | | 地点 | "全景•路演天下"（http://rs.p5w.net）互动平台 | | 上市公司接待人 | 董事长薛哲强、总经理黄珞、独立董事计云海、财务总监张为 | | 员姓名 | 结、董事会秘书张斌 | | | 本次 2023 广东辖区上市公司投资者关系管理月活动投资者集 体接待日以网络远程的方式举行，与线上投资者互动交流的主 | | ...

Group 1: International Expansion - The company has been actively exploring international markets with a "going out" strategy, focusing on selecting qualified local distributors for collaboration [2] - Employees are regularly sent to participate in international exhibitions to promote the brand and attract potential customers [2] - Sales personnel are divided into different regions with tailored sales targets and plans based on market characteristics and customer needs [2] Group 2: Accounts Receivable Management - The company's accounts receivable have decreased compared to the beginning of the year, and the current accounts receivable situation is considered healthy [2] - Major clients include public hospitals and large independent medical laboratories, with a direct sales model ensuring long-term business relationships [2] Group 3: Future Development Direction - The company has fully entered the IVD field, focusing on clinical diagnostics, public health, and related applications, with plans to strengthen PCR and molecular diagnostics [3] - There is an ongoing effort to diversify business areas and innovate existing products to meet growing customer demands [3] Group 4: Equity Incentive Plans - The company has attempted three equity incentive plans since its listing, with details published on designated information disclosure websites [3] - Despite challenges due to policy and objective conditions, the company remains committed to exploring equity incentives [3] Group 5: Investment Plans - The company continues to implement a "main business development + industry incubation" strategy, focusing on clinical diagnostic technologies and market expansion [3] - Since 2010, the company has successfully promoted industry chain development through investment strategies [3]

附件: 热泵以欢迎机构投资者 疫情态安装团购物 E L R R R R R R 注:左七为公司董事会秘书张斌与调研人员合影留念。 ...

证券代码：002030 证券简称：达安基因 公告编号：2023-038 医疗器械名称：丙型肝炎病毒核酸测定试剂盒（PCR-荧光探针法），注册证 编号：国械注准 20233401279。有效期自批准之日起至 2028 年 9 月 4 日。 上述医疗器械注册证的取得丰富了公司的产品组合，拓宽了公司产品的应用 领域。目前，上述产品尚处于市场开发阶段，市场需求存在不确定性，请广大投 资者注意投资风险。 特此公告。 广州达安基因股份有限公司 董 事 会 2023 年 9 月 6 日 广州达安基因股份有限公司 关于取得一个医疗器械注册证的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，广州达安基因股份有限公司（以下简称"公司"）取得国家药品监督 管理局颁发的医疗器械注册证一个，具体为： ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥536,218,449.35, a decrease of 91.97% compared to the same period last year[51]. - The net profit attributable to shareholders of the listed company was ¥402,755,388.71, down 88.80% year-on-year[51]. - The net profit after deducting non-recurring gains and losses was ¥102,897,120.82, a decline of 97.03% compared to the previous year[51]. - The net cash flow from operating activities was -¥38,382,493.67, a decrease of 102.25% compared to the same period last year[51]. - Basic earnings per share were ¥0.29, down 88.67% from ¥2.56 in the same period last year[51]. - Total assets at the end of the reporting period were ¥11,708,971,705.38, a decrease of 20.66% from the end of the previous year[51]. - The net assets attributable to shareholders of the listed company were ¥9,187,500,489.81, down 18.70% from the previous year[51]. - The weighted average return on net assets was 3.50%, a decrease of 36.95% compared to 40.45% in the same period last year[51]. - The company reported a total non-operating income of 299,858,267.89 CNY, with a significant portion attributed to non-recurring gains[73]. - The fair value changes from trading financial assets and derivatives generated a profit of 176,366,249.20 CNY, classified as regular operating income due to the nature of the business[73]. - The company reported a total profit for the period of CNY 487,312,008.57, down 88.76% year-on-year[114]. - The investment income decreased by 89.57% to ¥20,089,978.44, primarily due to the disposal of equity in joint ventures in the same period last year[172]. - The gross margin for the bioproducts sector was 52.32%, down by 23.50% year-on-year[175]. Environmental and Regulatory Compliance - The company has been classified as a key environmental risk control unit due to hazardous waste generation exceeding 100 tons per year, leading to stricter waste management protocols[9]. - The company has not experienced any sudden environmental incidents during the reporting period, and conducted emergency drills for hazardous chemicals in June 2023[10]. - The company has received multiple environmental impact assessment approvals for various projects, indicating ongoing expansion and compliance with regulatory requirements[30]. - The company’s major pollutants include noise, waste gas, wastewater, and solid waste, with noise levels recorded at 58.7 dB(A), below the standard limit of 60 dB(A)[32]. Strategic Initiatives and Market Position - The company is adapting to new market operational rules due to ongoing reforms in the pharmaceutical and healthcare sectors, particularly in the in vitro diagnostics industry[5]. - The company is exploring market expansion opportunities, particularly in the healthcare diagnostics sector, to leverage growth potential[75]. - The company is committed to enhancing its operational efficiency and profitability through strategic investments and product innovation[75]. - The company is actively pursuing strategic partnerships and potential acquisitions to bolster its capabilities and market reach[77]. - The company is focused on expanding its market presence through the introduction of new products and technologies, particularly in the field of infectious disease testing[77]. - The company has established a multi-level incentive mechanism to improve human resource management and enhance operational efficiency[145]. - The company has implemented a comprehensive performance and incentive management system to enhance employee morale and efficiency[119]. Research and Development - The company is investing in research and development to enhance its product offerings, particularly in the areas of genetic testing and infectious disease diagnostics[77]. - The company continues to invest in R&D, enhancing its core competitiveness through an efficient and open research platform[116]. - The company is focusing on research innovation and the application of new technologies and products to drive revenue and profit growth in the biopharmaceutical sector[4]. - The company emphasizes the importance of continuous technological innovation and new product launches in the IVD industry to maintain competitive advantage[192]. Product Portfolio and Market Trends - The company has a diverse product line including various nucleic acid testing kits for viruses such as COVID-19, hepatitis B, and influenza, indicating a strong focus on healthcare products[75]. - The company has launched a series of diagnostic products covering tumor markers, hepatitis, hormones, prenatal screening, and more, with multiple product approvals in 2022[1]. - The company has developed multiple advanced diagnostic technology platforms, including nucleic acid and immunological diagnostic technology[150]. - The company has over 500 registered medical device certificates and more than 100 invention patents, indicating a strong product reserve[151]. - The global IVD market is experiencing rapid growth, becoming a market worth hundreds of billions, with expectations for continued expansion due to new technologies and products[83]. - The domestic IVD product industry is rapidly developing, with accelerated innovation across various technology platforms and an increasing number of application products[85]. - The company has established itself as a leader in the molecular diagnostics industry, with prominent brands such as "Da An Gene" and "Da Rui Bio" leading the market[88]. Financial Management and Corporate Governance - The company has not undergone any bankruptcy reorganization during the reporting period[35]. - The company has not reported any changes in its board of directors or senior management during the reporting period[28]. - The company plans to not distribute cash dividends or issue bonus shares for the reporting period[19]. - The company has not reported any significant losses from entrusted loans or investment properties, indicating stable financial management[73]. - The company has not utilized any raised funds during the reporting period[187]. - There were no significant asset sales during the reporting period[188]. - The company does not engage in derivative investments during the reporting period[186].

广州达安基因股份有限公司（以下简称"公司"）全资孙公司达安国际集团 有限公司（以下简称"达安国际"）近日收到其参股公司云康集团有限公司（以 下简称"云康集团"）的现金分红款，具体情况如下： 根据云康集团于 2023 年 6 月 28 日召开的股东周年大会，其审议通过了"宣 派截至 2022 年 12 月 31 日止年度之末期股息每股 0.22 港元，自本公司股份溢价 账拨付"的议案。公司全资孙公司达安国际持有云康集团股份 209,783,000 股， 本次现金分红金额为 46,152,260.00 港元。 近日，公司全资孙公司达安国际已收到上述现金分红款 46,152,260.00 港元。 公司对云康集团的长期股权投资按权益法核算，该笔分红款对公司 2023 年度合 并报表净利润无影响。 证券代码：002030 证券简称：达安基因 公告编号：2023-033 广州达安基因股份有限公司 关于全资孙公司收到现金分红款的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 2023 年 8 月 28 日 特此公告。 广州达安基因股份有限公司 董 事 会 ...

附件： + 热烈欢迎中情压势、 8月1日 38:本 475455 [19] 101 注：图右一为公司董事会秘书张斌与调研人员合影留念。 ...